Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric ...

Lantern Pharma (NASDAQ: LTRN) reported strong preclinical results for LP-184 in atypical teratoid rhabdoid tumors (“ATRT”), a rare and aggressive ped ...

UT Southwestern Medical Center scientists have identified a protein that appears to act as a master control switch for ...

You’re seeing hundreds of images mosaic together to encompass the whole fly brain from tip to tip.” On a large monitor, the ...

Study suggests gasdermin D inhibition may protect mice by blocking release of cellular contents into the extracellular ...

Treatment for Parkinson's focuses on managing its many symptoms, as there is no cure. But a new stem cell therapy developed at Memorial Sloan Kettering Cancer Center for advanced Parkinson's is ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research ...

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited ...

In the largest ever study of its kind, an analysis of entire tumor genomes has provided the most complete picture yet of an ...

Due to the sudden rupture of the aortic wall, aortic dissection is a life-threatening condition that requires immediate ...

A lab-designed molecule developed and extensively studied could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor ...